Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD
Munich, Germany – 25 March 2026: Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapies for complement-mediated diseases,…